Intrahepatic Cholangiocarcinoma  >>  erlotinib  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
erlotinib / Generic mfg.
NCT00033462: Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

Completed
2
78
US
erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, laboratory biomarker analysis
National Cancer Institute (NCI)
Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
11/06
 
NCT00356889: Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors

Checkmark P2 data-ESMO-GI
Jun 2012 - Jun 2012: P2 data-ESMO-GI
Completed
2
56
US
erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF
National Cancer Institute (NCI)
Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Gastrointestinal Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
10/08
06/10
NCT01093222: Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Checkmark Sorafenib & erlotinib in pts with adv gallbladder carcinoma or cholangiocarcinoma
Jan 2014 - Jan 2014: Sorafenib & erlotinib in pts with adv gallbladder carcinoma or cholangiocarcinoma
Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
2
40
US
Erlotinib Hydrochloride, Cp-358,774, OSI-774, Tarceva, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib
National Cancer Institute (NCI)
Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma, Gallbladder Adenocarcinoma With Squamous Metaplasia, Hilar Cholangiocarcinoma, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Undifferentiated Gallbladder Carcinoma, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma
09/12
09/14
NCT00832637: Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers

Terminated
2
33
US
Cisplatin, Platinol®, Erlotinib, Tarceva®, Gemcitabine, Gemzar®
New Mexico Cancer Care Alliance
Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer, Periampullary Adenocarcinoma, Gallbladder Cancer, Extrahepatic Bile Duct Cancer
06/13
03/17

Download Options